Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Lotiglipron in Participants with Hepatic Impairment
NCT05478603Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 144 hours, Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time at 144 hours and 5 more. Started Aug 2022; status: completed.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05478603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478603.